

ENCYCLOPEDIA OF PHARMACEUTICAL TECHNOLOGY

Editors

JAMES SWARBRICK

Vice President
Research and Development
AAI, Inc.
Wilmington, North Carolina

JAMES C. BOYLAN

Director
Pharmaceutical Technology
Hospital Products Division
Abbott Laboratories
Abbott Park, Illinois

VOLUME 13

PRESERVATION OF PHARMACEUTICAL PRODUCTS TO SALT FORMS OF DRUGS AND ABSORPTION

MARCEL DEKKER, INC., NEW YORK • BASEL • HONG KONG

**Pharmacy Library
University of Wisconsin - Madison
2130 Chamberlin Hall
425 N. Charter Street
Madison, WI 53706-1508**

Library of Congress Cataloging in Publication Data

Main entry under title:

Encyclopedia of Pharmaceutical Technology.
editors: James Swarbrick, James C. Boylan.

Includes index.

1. Pharmaceutical technology—Dictionaries. I. Swarbrick, James.
II. Boylan, James C.
[DNLM: 1. Chemistry, Pharmaceutical-encyclopedias. 2. Drugs—
encyclopedias. 3. Technology, Pharmaceutical-encyclopedias. QV 13 E565].
RS192.E53 1988 615'.1'0321-dc19

COPYRIGHT © 1996 BY MARCEL DEKKER, INC. ALL RIGHTS RESERVED.

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher.

MARCEL DEKKER, INC.
270 Madison Avenue, New York, New York 10016

LIBRARY OF CONGRESS CATALOG CARD NUMBER 88-25664
ISBN: 0-8247-2812-2

Current printing (last digit):
10 9 8 7 6 5 4 3 2 1

PRINTED IN THE UNITED STATES OF AMERICA

Salt Forms of Drugs and Absorption

Introduction

Salt formation is frequently performed on weak acidic or basic drugs because it is a relatively simple chemical manipulation which may alter the physicochemical, formulation, biopharmaceutical, and therapeutic properties of a drug without modifying the basic chemical structure. Salt selection has been largely semi-empirical, based on consideration of cost of raw materials, yield, ease of preparation and purification, etc. Although attempts have been made to apply "decision analysis" and "potential problem analysis" to select salts and help predict salt performance [1], the choice of which salt to use remains a difficult decision.

The ideal characteristics of a salt are that it is chemically stable, not hygroscopic, presents no processing problems, dissolves quickly from solid dosage forms (unless it is formed with the intent to delay dissolution), and exhibits good bioavailability.

The literature contains a large amount of information on salts; however, much of the early research addresses the use of salt formation to prolong the release of the active component, thereby eliminating various undesirable drug properties[2-6]. This article supplements an extensive review published in 1977 [7], providing a literature overview of approximately 40-45 years. Its objectives are to present potentially useful salts, their effect on the properties of the parent drug, and a decision tree for choosing the most desirable salt form(s) for development.

Potentially Useful Salts

Salt formation is one of the simplest chemical reactions, involving either a proton transfer or a neutralization reaction between an acid and a base. The relative strength of the acid or base, or the acidity and basicity constants of the species involved, significantly influences the occurrence of the reaction and provides a measure of the stability of the resulting salt. Theoretically, every compound possessing acidic and/or basic properties can participate in salt formation.

Salt forms that have been clinically evaluated in humans or were commercially marketed through 1993 are shown in Tables 1 and 2, compiled from the drug monographs listed in *Martindale, The Extra Pharmacopoeia*, 30th-ed. [8]. Table 1 gives all anionic salt forms, Table 2 all cationic forms. The relative frequency (as a percentage) of use for each salt type was calculated based on the total number of anionic or cationic salts used through 1993.

The monoprotic hydrochlorides are by far the most frequent choice of an anionic salt-forming radical, probably for physiological reasons and simple availability. For similar reasons, sodium is the most predominate cation. These findings are identical to those reported in a similar survey [7] from 1977, even though they are based on twice the number of salts as the earlier study. Other comparisons between this and the previous review show an increase of approximately 40% in the types of anionic salts and approxi-

TABLE 1 Anionic Pharmaceutical Salt Forms Currently in Use

Anion	Percent ^a	Anion	Percent ^a	Anion	Percent ^a
Aceglumate	0.07	Formate	0.07	Nicotinate	0.13
Acetylglucuronate (7-Theophyllineacetate)	0.26	Fosfatex (Metaphosphate)	0.07	Nitrate	1.18
Acetamidobenzoate	0.07	Fumarate	0.92	Oleate	0.13
Acetate	2.09	Glucetate (Glucoheptonate)	0.13	Orotate	0.26
Acetylasparaginate	0.07	Gluconate	0.52	Oxalate	0.26
Acetylaspartate	0.07	Glucuronate	0.13	Oxoglurate	0.13
Adipate	0.13	Glutamate	0.07	Parnate (Embonate)	1.37
Aminosalicylate	0.13	Glycerophosphate	0.52	Pantothenate	0.07
Anhydromethylenecitrate	0.07	Glycinate	0.13	Pectinate	0.07
Ascorbate	0.13	Glycolylarsinilate (p-Glycollamidophenylarsionate)	0.07	Phenylethylbarbiturate	0.13
Aspartate	0.33	Glycyrrhizate	0.07	Phosphate	2.48
Benzoate	0.20	Hippurate	0.07	Picrate	0.07
Besylate (Benzenesulfonate)	0.26	Hemisulfate	0.13	Policrilix (Methacrylic acid polymer)	0.07
Bicarbonate	0.07	Hexylresorcinate	0.07	Polistirex ^b	0.85
Bisulfate	0.13	Hybenzate o-(4-Hydroxybenzyl)benzoate	0.20	Polygalacturonate	0.07
Bitartrate	0.52	Hydrobromide	1.37	Propionate	0.20
Borate	0.26	Hydrochloride	43.99	Pyridoxylphosphate	0.13
Bromide	3.79	Hydroiodide	0.07	Saccharinate	0.20
Butylbromide	0.07	Hydroxybenzenesulfonate	0.07	Salicylate	0.78
Camphorate	0.01	Hydroxybenzoate	0.07	Stearate	0.20
Camsylate (Camphorsulfonate)	0.59	Hydroxynaphthoate	0.07	Stearylsulfate	0.07

Salt Forms of Drugs and Absorption

Carbonate	0.46	Iodide	1.11	Subacetate	0.07
Chloride	3.53	Isethionate (2-Hydroxyethanesulfonate)	0.52	Succinate	0.52
Chlorophenoxyacetate	0.07	Lactate	0.98	Sulfate	5.82
Citrate	2.81	Lactobionate	0.07	Sulfosalicylate	0.07
Closylate (4-Chlorobenzenesulfonate)	0.07	Lysine	0.65	Tannate	0.85
Cromesilate (6,7-Dihydroxycoumarin-4-methanesulfonate)	0.07	Malate	0.26	Tartrate	2.68
Cyclamate	0.13	Maleate	3.14	Teprosilate ^c	0.07
Dehydrocholate	0.07	Mandalate	0.13	Terephthalate	0.07
Dihydrochloride	1.37	Mesylate	3.20	Teoclate (8-Chlorotheophyllinate)	0.33
Dimalonate	0.07	Methylbromide	0.39	Thiocyanate	0.20
Edetate	0.07	Methyliodide	0.20	Tidiacate (Thiazolidine-2,4-dicarboxylate)	0.07
Edisylate (1,2-Ethanedisulfonate)	0.20	Methylnitrate	0.13	Timonacicate (Thiazolidine-4-carboxylate)	0.07
Estolate (Lauryl sulfate)	0.13	Methylsulfate	0.98	Tosylate (Toluene-4-sulfonate)	0.39
Esylate (Ethanesulfonate)	0.13	Monophosadenine (Adenylic acid)	0.07	Triethiodide	0.07
Ethylbromide	0.07	Mucate	0.07	Undecanoate	0.13
Ethylsulfate	0.07	Napadisylate	0.13	Xinafoate (1-Hydroxyl-naphthoate)	0.07
Fendizoate (Hydroxyphenylbenzoylbenzoate)	0.07	Napsylate (1,5-Naphthalenedisulfonate)	0.20		

^aPercent is based on total number of anionic salts in use through 1993.

^bSulfonated diethylenylbenzene-ethylenylbenzene copolymer complex.

^c1,2,3,6-Tetrahydro-1,3-dimethyl-2,6-dioxopurine-7-propanesulfate.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.